

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/678,836
Filing Date	10-03-2003
First Named Inventor	Manoussos Perros
Art Unit	1625
Examiner Name	Amelia A. Owens
Attorney Docket Number	PC19025B

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER Number-Kind Code <sup>2</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
IAOI		CHOE, H., et al., "The $\beta$ -Chemokine Receptors CCR3 And CCR5 Facilitate Infection By Primary HIV-1 Isolates," <i>Cell</i> , 1996, 1135-1148, vol. 85.	
IAOI		FATKENHEUER, g., et al., "Efficacy Of Short-Term Monotherapy With Maraviron, A New CCR5 Antagonist, In Patients Infected With HIV," <i>Nature Medicine</i> , 2005, 1170-1172, vol. 11, no. 11.	
IAOI		LITTMAN, D., et al., "Chemokine Receptors: Keys To AIDS Pathogenesis?" <i>Cell</i> , 1998, 677-680, vol. 93.	
IAOI		ZHANG, L., et al., "In Vivo Distribution Of The Human Immunodeficiency Virus/Simian Immunodeficiency Virus Coreceptors: CXCR4, CCR3, And CCR5," <i>Journal of Virology</i> , 1998, 5035-5045, vol. 72, no. 6.	
IAOI		ZHANG, L., et al., "Chemokine Coreceptor Usage By Diverse Primary Isolates Of Human Immunodeficiency Virus Type 1," <i>Journal of Virology</i> , 1998, 9307-9312, vol. 72, no. 11.	
IAOI		Progenics Reports Discovery Of CCR5 Structure That Binds HIV – Advances Development Of New Class Of HIV Fusion Inhibitors, 2000, PRNewswire, Taos, New Mexico.	

EXAMINER: /Amelia Owens/

DATE CONSIDERED:

8/21/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.